Nachrichten zur PLUS THERAPEUTICS Aktie

…

…

Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the…

Plus (PSTV) delivered earnings and revenue surprises of -229.41% and 42.76%, respectively, for the quarter ended March 2025. Do the…

Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the…

The FDA conditionally accepts Plus Therapeutics new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.…

The FDA bestows an Orphan Drug tag to Plus Therapeutics investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in…

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium…

…

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership…

Plus Therapeutics granted extension by Nasdaq…

…

…

…